Printer Friendly

CYTOGEN WELCOMES MICHAEL R. KURMAN AS DIRECTOR OF CANCER THERAPEUTICS, CLINICAL INVESTIGATIONS

 PRINCETON, N.J., June 4 /PRNewswire/ -- CYTOGEN (NASDAQ: CYTO) announced today that Michael R. Kurman, M.D., has joined the Clinical Investigations Department of the Company as Director of Cancer Therapeutics, with the responsibility for managing clinical trials of OncoRad(R) Ovarian, the company's ovarian cancer therapeutic product in Phase II clinical trials, and the newly acquired pain relief agent for bone cancer, Samarium-EDTMP, currently in Phase III clinical trials. Kurman has more than 11 years of oncologic experience, in both private practice and most recently, overseeing clinical trials in the position of director of Oncology and Allergy with Janssen Pharmaceutica, U.S.A.
 Kurman joined Janssen as director of Oncology in 1989, and served as Assistant to the Vice President for Licensing and Acquisitions in 1991. Dr. Kurman was a practicing oncologist from 1982 to 1989. He received his M.D. degree from Cornell University Medical College, received internal medicine training at the State University of New York, Upstate Medical Center, and has completed a medical oncology fellowship at Mt. Sinai Medical Center.
 Vice President of Clinical Investigations Robert T. Maguire, M.D., commented, "We are extremely pleased with the addition of Michael Kurman to CYTOGEN's clinical investigations team. His previous clinical management experience will significantly contribute to the continued forward momentum of CYTOGEN's cancer therapeutic program."
 CYTOGEN is a biopharmaceutical company engaged in the development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. CYTOGEN uses its patented and proprietary "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 6/4/93
 /CONTACT: Mary Beals, director of Corporate Communications of CYTOGEN, 609-987-8221/
 (CYTO)


CO: CYTOGEN Corporation ST: New Jersey IN: MTC SU: PER

CC -- PH021 -- 5474 06/04/93 13:22 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 4, 1993
Words:297
Previous Article:OMEGA ANNOUNCES 15 PERCENT DIVIDEND INCREASE
Next Article:INTERMARK INC. AND TRITON GROUP LTD.ANNOUNCE CONFIRMATION OF PLAN OF REORGANIZATION
Topics:


Related Articles
CYTOGEN ANNOUNCES 1992 ANNUAL MEETING HIGHLIGHTS
CYTOGEN AND CYTORAD INITIATE CLINICAL TRIALS OF CANCER THERAPY AGENT
CYTOGEN ACQUIRES RIGHTS TO UNILEVER CANCER PROGRAM
CYTOGEN AND CYTORAD ANNOUNCE EXPANDED AGREEMENT
CYTOGEN SIGNS AGREEMENT WITH THE IMPERIAL CANCER RESEARCH TECHNOLOGY AND CONFIRMS THIRD QUARTER RESULTS
CYTOGEN TO ACQUIRE CELLCOR, INC.
Advanced Magnetics' Combidex(R) to be Reviewed by FDA Oncologic Drugs Advisory Committee.
Presentations at RSNA Suggest Combidex(R) Useful in Detecting the Spread of Cancer to Lymph Nodes; -- Studies Show Potential Role for Combidex in a...
Presentations at ISMRM Suggest Combidex(R) Useful in Detecting the Spread of Breast and Prostate Cancers to Lymph Nodes.
New Data Shows Feasibility of Semi-Automated Analysis of Combidex(R)-Enhanced MRI.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters